SYDNEY, March 17, 2023 /PRNewswire/ — SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the…
